Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 11/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
| ▸ | MYLK4 | Q86YV6 | 2/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.40 |
| ▸ | NUAK1 | O60285 | 4/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048193 | 0.91 | ZAP70 (0.60) | ZAP70 | |
| SCHEMBL1050495 | 0.90 | ZAP70 (0.47) | ZAP70PTK2MAP4K1MYLK4STK17A | |
| SCHEMBL1046976 | 0.87 | ZAP70 (0.47) | ZAP70PTK2MAP4K1NUAK1AURKB | |
| SCHEMBL1049200 | 0.87 | ZAP70 (0.61) | ZAP70 | |
| SCHEMBL12929910 | 0.86 | ZAP70 (0.59) | ZAP70 | |
| SCHEMBL1047095 | 0.86 | ZAP70 (0.55) | ZAP70 | |
| SCHEMBL1043452 | 0.84 | ZAP70 (0.57) | ZAP70 | |
| SCHEMBL1050428 | 0.83 | ZAP70 (0.56) | ZAP70 | |
| SCHEMBL1048671 | 0.83 | ZAP70 (0.66) | ZAP70 | |
| SCHEMBL1048064 | 0.83 | ZAP70 (0.49) | ZAP70MYLK4STK17A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| CN-101990539-A | Compounds and compositions as kinase inhibitors | IRM LLC | 2011-03-23 | — | — | CN | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | disclosed |
| WO-2009097287-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | ZAP70 4/4885PTK2 54/4885MAP4K1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.